AMYVID Solution for injection Ref.[10078] Active ingredients: Florbetapir ¹⁸F

Source: FDA, National Drug Code (US)  Revision Year: 2020 

Product description

Amyvid contains florbetapir F 18, a molecular imaging agent that binds to β-amyloid aggregates, and is intended for use with PET imaging of the brain. Chemically, florbetapir F 18 is described as (E)4(2-(6-(2-(2-(2[18F] fluoroethoxy)ethoxy)ethoxy)pyridine-3-yl)vinyl)-N-methylbenzamine. The molecular weight is 359 and the structural formula is:

Amyvid is a sterile, non-pyrogenic radioactive diagnostic agent for intravenous injection. The clear, colorless solution is supplied ready to use and each milliliter contains 0.1 to 19 micrograms of florbetapir and 500-1900 MBq (13.5-51 mCi) florbetapir F 18 at EOS, 4.5 mg sodium ascorbate USP and 0.1 mL dehydrated alcohol USP in 0.9% sodium chloride injection USP. The pH of the solution is between 5.5 and 8.0.

11.1 Physical Characteristics

Amyvid is radiolabeled with [18F] fluorine (F 18) that decays by positron (β+) emission to O 18 and has a half-life of 109.77 minutes. The principal photons useful for diagnostic imaging are the coincident pair of 511 keV gamma photons, resulting from the interaction of the emitted positron with an electron (Table 3).

Table 3. Principal Radiation Produced from Decay of Fluorine 18:

RadiationEnergy Level (keV) Abundance (%)
Positron249.896.9
Gamma511193.5

11.2 External Radiation

The point source air-kerma coefficient a for F-18 is 3.74E -17 Gy m 2/(Bq s); this coefficient was formerly defined as the specific gamma-ray constant of 5.7 R/hr/mCi at 1 cm. The first half-value thickness of lead (Pb) for F 18 gamma rays is approximately 6 mm b. The relative reduction of radiation emitted by F-18 that results from various thicknesses of lead shielding is shown in Table 4. The use of ~8 cm of Pb will decrease the radiation transmission (i.e., exposure) by a factor of about 10,000.

Table 4. Radiation Attenuation of 511 keV Gamma Rays by Lead Shielding:

Shield Thickness cm of lead (Pb) Coefficient of Attenuation
0.60.5
20.1
40.01
60.001
80.0001

a Eckerman KF and A Endo. MIRD: Radionuclide Data and Decay Schemes, 2 nd Edition, 2008.
b Derived from data in NCRP Report No. 49. 1998, Appendix C

Dosage Forms and Strengths

Amyvid (Florbetapir F 18 Injection) is available in a 30 mL and 50 mL multidose vial containing a clear, colorless solution at a strength of 500-1900 MBq/mL (13.5-51 mCi/mL) florbetapir F 18 at End of Synthesis (EOS).

How Supplied

Amyvid is supplied in 30 mL or 50 mL vials containing 10-30 mL or 10-50 mL, respectively, of a clear, colorless solution at a strength of 500-1900 MBq/mL (13.5-51 mCi/mL) florbetapir F 18 at EOS. Each vial contains multiple doses and is enclosed in a shielded container to minimize external radiation exposure.

30 mL NDC 0002-1200-30 (IC1200)
50 mL NDC 0002-1200-50 (IC1200)

Drugs

Drug Countries
AMYVID Austria, Estonia, Croatia, Ireland, Japan, Lithuania, Poland, United States

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.